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Bartter's syndrome with hyperplasia of renomedullary cells: Suc-
cessful treatment with indomethacin. During treatment with in-
domethacin in a patient with Banter's syndrome, hypokalemia,
high plasma renin concentration, hyperaldosteronism and de-
creased sensitivity to angiotensin infusion were corrected. A par-
ticular finding in the renal biopsy specimen was a marked hyper-
plasia of renomedullary interstitial cells which had characteristics
similar to the cells known to produce renal prostaglandins. The
hypothesis is formulated that the primary defect in this syndrome
is related to hyperplasia of renomedullary interstitial cells and
inappropriate release of renal prostaglandins giving rise to de-
creased sodium reabsorption, volume depletion and hypersecretion
of renin and aldosterone.
Syndrome de Bartter avec hyperplasie des cellules rénomédul-
laires: Succès thérapeutique de I'indométhacine. Au eours d'un
traitement par l'indométhacine d'un malade atteint de syndrome
de Bartter l'hypokaliemie, l'élévation de Ia concentration plas-
matique de rénine, l'hyperaldostéronisme et Ia diminution de Ia
sensibilité a La perfusion d'angiotensine ont été cornigés. Une
découverte particulière dans l'étude de Ia biopsie rénale a été
l'hyperplasie marquee des cellules interstitelles rénomédullaires
qui avaient des caractères semblables a ceux des cellules connues
pour produire les prostaglandines rénales. L'hypothèse est
formulée que Ia cause primaire de cc syndrome est liée a l'hyper-
plasie des cellules interstitielles rénoméduilaires et a une liberation
inadequate de prostaglandines ce qui entraIne une diminution
de La reabsorption du sodium, une diminution des liquides extra-
cellulaires, une hypersecrétion de rénine et d'aldostérone.
It has been suggested that, at least in some patients,
Bartter's syndrome results from an obligatory renal
tubular loss of sodium due to an acquired injury to
the kidney, resulting in hypovolemia, overproduction
of renin and aldosterone, hypokalemia and resistance
to the action of angiotensin [1-3].
The treatment usually consists of spironolactone
and dietary manipulations directed toward normali-
zation of the serum electrolyte pattern [4-6]. This
treatment, which is often less than satisfactory, is not
directed against the sodium loss, but aims at the
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correction of a secondary phenomenon. Further-
more, treatment with spironolactone may accentuate
the sodium loss.
Under certain conditions, indomethacin reduces
renal blood flow and stimulates fractional tubular
sodium reabsorption, probably as a consequence of
decreased renal prostaglandin synthesis [7-9]. Theo-
retically, thus, indomethacin could be used in an
attempt to correct the major defect in patients with
Bartter's syndrome.
In this paper we report the successful use of in-
domethacin in a patient with Bartter's syndrome.
This observation, together with the finding of hyper-
plastic renomedullary interstitial cells, known to be
the site of production of renal prostaglandins, could
throw some light on the pathogenesis of the
syndrome.
Case report
At the time of the study (February, 1975), the
patient was a 25-yr-old white man with normal phys-
ical and mental development. The diagnosis of Bart-
ter's syndrome had been made 18 months previously
on the basis of the following findings: muscle weak-
ness, normal blood pressure, hypokalemia (+ 1.5
mEq/liter), increased serum bicarbonate concentra-
tions, elevated plasma renin concentration and
hyperplasia of the juxtaglomerular apparatus (see
Fig. 1). Other known causes of hypokalemia as-
sociated or not with high renin concentrations and
with normal blood pressure were excluded: abuse of
licorice, laxatives or diuretics, anorexia nervosa,
diabetes insipidus, pyelonephritis. A treatment
with spironolactone, 150 to 225 mg daily, and
potassium supplements was prescribed. This re-
sulted initially in a satisfactory increase of serum
potassium concentration to 3 to 3.5 mEq/liter and
Barn ers syndrome treated with indomethacin 303
same treatment (indomethacin, 150 mg daily). Since
the institution of the indomethacin treatment, the
patient has remained free of symptoms for a period of
more than eight months until now and the serum
potassium concentration remained within the normal
range. An attempt to reduce the dose to 100 mg
caused recurrence of hypokalemia Serum creatinine
concentrations and creatinine clearance remained un-
changed at 1.5 mg/100 ml and 60 ml/min, respec-
tively, during the whole period of observation.
Special studies
After 14 days of treatment with indomethacin,
urinary sodium and potassium excretion were meas-
ured daily during a 17-day period of fixed sodium and
potassium intake (Fig. 3). After a control period of
five days, the indomethacin treatment was inter-
rupted for seven days and resumed thereafter. Inter-
ruption of the treatment with indomethacin resulted
in a rapid loss of body weight (3 kg), the serum
total protein concentration increased from 7.60 to
8.85 g/liter and the serum potassium concentration
decreased from 3.60 to 2.2 mEq/liter. The sixth day
after resumption of the treatment, the body weight
70
Fig. 1. Hypertrophy of the juxtag1ome1ar apparatus (X310). Weight
68
kg 6
disappearance of the symptoms. During the six 6
months preceding the hospitalization, however, a de-
crease in serum potassium concentrations was ob- 10
served notwithstanding continued treatment. On Jan- Plasma
uary 30, 1975, the patient was again admitted because proteinconc. 8
of pronounced muscle weakness and marked hypoka- g/liter
lemia (1.5 mEq/liter). The dose of spironolactone
was increased to 300 mg daily, with some increase of 125
serum potassium concentrations; however, symptoms Blood 105[ i
of postural hypotension developed. Indomethacin, pressure 85 I I I i I I I I I I I i I Imm Hg150 mg daily, was then added to the treatment (Fig. 65L ] I I I I 11111
2). It resulted in fluid retention as manifested by a
rapid increase in weight, decrease of sodium excre-
tion, decrease of serum total protein concentration 4
and of hematocrit value. The serum potassium con- Serum K
centration increased further to normal levels with mEqiliter
decreasing urinary potassium excretion. After in-
terruption of spironolactone and potassium sup- Spironolactone' -
plements, the serum potassium concentrations re- mg/day 300 ____________________
mained within normal limits under treatment with Indomethacin
ng/day 150 _______________________indomethacin alone. A sodium and potassium bal-
ance study was then performed in order to observe I I I I I I I I I I I I I I I I
the effects of interruption and resumption of the Days
treatment with indomethacin (see Special studies). Fig. 2. Influence of changing the treatment from aldactone, 300 mg
The patient was discharged on March 11 with the to indomethacin, 150 mg daily.
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our patient, both values were normal before the inter-
ruption of the treatment, frankly elevated during the
interruption and nearly normal at the end of the
treatment (Fig. 3).
The response of blood pressure and pulse rate to
the i.v. infusion of stepwise increasing doses of angio-
tensin differed significantly in the period before
and after interruption of the treatment with
42 indomethacin. During treatment a significant in-
36 crease in blood pressure and a decrease in the pulse
rate was observed at an infusion rate of 0.02
tg/kg/min. During the test performed in the pe-
riod without treatment, the pulse pressure was
smaller and the increase in blood pressure was less
pronounced even at much higher infusion rates; the
pulse rate decreased only at the infusion rate of 0.40
tg/kg/min (Fig. 4).
Erythrocyte potassium concentration was meas-
ured using inulin as an indicator of trapped plasma.
The mean value found in 12 normal individuals was
94 mEq/liter +4.5 (SD). After five days of interrup-
tion of indomethacin, the erythrocyte potassium
concentration was 86 mEq/liter. After resumption of
the treatment, a value of 94 mEq/liter was found.
Histological findings
The corticomedullary renal biopsy performed dur-
ing the first hospitalization contained six glomeruli
_________________________________
per section. The glomerular tufts showed no abnor-
mality. The juxtaglomerular apparatuses were cx-
°ii
Weight 68L
kg
66 L
9
Plasma protein cone. 8F
g/liter
7'-
Plasma renin conc. + + +
U/mI 14 330200
Plasma aldost-erone cone. 16 154
ng/100 ml
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Serum K 3!-
mEg/liter
L
21
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II
Urinary Na
mEq/24 hr
I nd ornetha cm
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Fig. 3. Influence of inlerrup lion and resumption of treatment with
indomethacin. The dotted lines represent the level of sodium and
potassium intake.
had again increased by more than 3 kg, the serum
total protein concentration was 7.65 g/liter, and the
serum potassium level, 3.4 rnEq/liter. No significant
changes in serum sodium concentration were ob-
served. Some sodium loss was manifest only on the
first day after interruption of indomethacin, and so-
dium retention was found only on the first two days
after resumption of the treatment. In contrast, the
changes of the potassium excretion were much more
pronounced. Potassium loss became manifest on the
second day after interruption of the treatment and
amounted to 350 mEq/Iiter in five days. After re-
sumption of the treatment, potassium retention was
found from the second day on and amounted to 310
mEq in five days.
Plasma renin concentration was measured with the
method of Skinner [10], plasma aldosterone concen-
tration by radioimmunoassay [II]. Normal values
are < IOU U/mI and <40 ng/lOO ml, respectively. In
Fig. 4. Influence of angiolensin injitsion on blood pressure and pulse
rate during treatment with indomethacin (upper curve) and after
interruption of the treatment (lower curve).
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The collecting tubules showed perinuclear vacu-
oles, and some PAS-positive dots. The Henle loops,
and the vascular endothelia, showed striking eosino-
philia and accumlations of PAS-, silver- and sudan
black-positive droplets, which were also auto-
fluorescent.
Discussion
Fig. 5. Hyperplasia of renomedullary interstitial cells (X310). The
picture Consists mainly of these peculiar cells, separating the nor-
mal structural elements of the medulla.
tremely prominent, and contained numerous PAS-
and methenamine silver-positive droplets. The ma-
culae densae were unusually large (Fig. 1). Due to
lack of tissue, no Bowie stains were performed.
The tubules were dilated. The epithelium of the
proximal tubules was flattened and contained large
vacuoles sometimes bulging into the tubular lumen.
In some of the distal tubules, a few silver-positive
droplets were observed. There was a slight but defi-
nite interstitial fibrosis. A few tubules were atrophic,
with a widened basement membrane.
In the medulla a peculiar widened hypercellular
interstitium was found. This consisted mostly of
polyhedral, sometimes rather fusiform cells with a
finely granular, eosinophilic cytoplasm (Fig. 5).
These cells were embedded in a fine collagen mesh-
work, which was also PAS-positive. Some of these
cells were vacuolated but no material could be de-
tected in these vacuoles. The cytoplasm contained a
few PAS- and silver-positive dots. Further staining
characteristics are given in Table 1.
The observation that indomethacin successfully
replaced spironolactone in the treatment of this pa-
tient with Bartter's syndrome was confirmed by the
findings after withdrawal and resumption of indo-
methacin during the balance study. The data
clearly indicate that withdrawal of indomethacin in-
duced loss of body fluid as indicated by the rapid
decrease in body weight and the concommitant in-
crease in serum protein concentration. It is
remarkable, however, that these changes in fluid bal-
ance were reflected much more in the changes of the
potassium balance than in the changes of the sodium
balance. The magnitude of the cumulative changes in
potassium balance ( > 300 mEg) makes it logical to
assume that the treatment induced intracellular reten-
tion of potassium, whereas withdrawal of the treat-
ment resulted in decreased intracellular potassium
content. The increase of erythrocyte potassium con-
centration found in our patient after resumption of
the indomethacin treatment is in accordance with this
assumption. Decreased intracellular potassium con-
centration has been reported in other patients with
Bartter's syndrome [4]. The fact that the changes in
potassium balance occurred only from the second
day after the change in treatment, whereas the
changes in sodium balance were most conspicuous on
the first day after the change in treatment, indicates
that the changes in potassium balance were probably
secondary to changes in the extracellular sodium and
fluid balance. Thus, for the observed changes the
following mechanism can be proposed. After with-
drawal of indomethacin some decrease in extra-
cellular volume occurred, stimulating renin and
aldosterone secretion which decreased the sodium
Table 1. Comparison of histochemical characteristics of interstitial
cells of the renal medulla in our patient and in renomedullary
interstitial cell tumors studied by Lerman et al [Ill
Patient Lerman et al
PAS intracellular + +
Alcian blue + +
Colloidal iron + +
OilredO + +
Sudan black + +
PAS extracellular + +
Collagen + +
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loss while initiating potassium depletion. After re-
sumption of the treatment, sodium retention oc-
curred decreasing the renin and aldosterone secretion
and thus initiating potassium retention. The observed
changes in the plasma renin and plasma aldosterone
concentrations are in agreement with this hypothesis.
These data support the suggestion of others that, at
least in some patients, Bartter's syndrome appears to
be the result of a renal tubular defect in the handling
of sodium [1,2]. The finding that fluid and electrolyte
retention during indomethacin treatment in our
patient resulted in a reversal of the insensitivity to
angiotensin is consistent with the hypothesis that this
insensitivity is a secondary phenomenon. Angio-
tensin insensitivity has indeed been reported with
volume depletion and high endogenous angiotensin
II concentrations [12].
The histologic findings in our patient include well-
known features of Bartter's syndrome: hyperplasia of
the juxtaglomerular apparatus and lesions typically
found in chronic hypokalemia, such as vacuolization
of cortical tubules and the presence of inclusions in
the epithelia of the collecting tubules, Henle's loops,
the vascular epithelia and the interstitial cells of the
medulla. More interesting was the finding of massive
hyperplasia of the interstitial cells of the medulla.
These cells are similar to those found in the so-called
renomedullary interstitial cell tumors as described by
Lerman et al [13]. A comparison of the histochemical
characteristics of the hyperplastic cells found in our
patient and in the cases described by Lerman et al is
given in Table 1. The renomedullary interstitial cells
have received special attention in recent years as they
are the probable site of production of vasoactive
lipids extractable from the renal medulla [13-16].
Grown in tissue culture they are shown to synthetize
renal prostaglandins [17]. It is assumed that the renal
prostaglandins may circulate intrarenally to the cor-
tex [18,19], thereby inducing their well-known effects
of cortical vasodilation and natriuresis [20,21]. These
effects are abolished by administration of substances
such as indomethacin which are known to be inhib-
itors of prostaglandin synthetase, the enzyme that
catalyzes the first step in the synthesis of prosta-
glandins from arachidonic acid [7-9].
The remarkable efficacy of indomethacin in our
patient could be due to an aspecific sodium-retaining
action. It is tempting, however, to relate the effect of
indomethacin treatment t the existence of hyper-
plastic renomedullary interstitial cells. Indeed, if this
hyperplasia is related to enhanced elaboration of pros-
taglandins, then the efficacy of indomethacin could
be related to its properties as a prostaglandin synthet-
ase inhibitor. The following hypothesis concerning
the pathogenesis of Bartter's syndrome in this patient
can thus be formulated: some unknown factor giving
rise to hyperplasia of the renomedullary interstitial
cells and inappropriate release of prostaglandins is
the primary defect causing decreased sodium reab-
sorption, volume depletion, angiotensin insensitivity,
increased renin secretion and secondary hyperaldos-
teronism. As angiotensin is known to be a potent
stimulus of prostaglandin secretion [22], it could be
argued that the hyperplasia of the renomedullary
interstitial cells is the mere consequence of the hyper-
plasia of the juxtaglomerular apparatus. However,
the fact that the treatment with indomethacin was
found to normalize the plasma renin concentration
is an argument in favor of the hypothesis that the
hyperplasia of the renomedullary interstitial cells is
the primary, and the hyperplasia of the juxta-
glomerular apparatus is the secondary, defect in this
syndrome. This hypothesis, of course, requires
further confirmation. In this connection, it should
be noted that hyperplasia of interstitial cells in the
renal medulla has been mentioned in at least two
other reported cases of Bartter's syndrome [23, 24].
Furthermore, indomethacin was recently found to be
effective in other patients with Bartter's syndrome
(Bartter FC, Fichman MP: personal communica-
tions).
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